TB-500 fragment
Not FDA approvedThymosin beta-4 derived peptide
Also known as: TB4 fragment, Ac-SDKP, thymosin beta-4 fragment
Very thin human evidence
- Regulatory standing. Sold as a research chemical, not approved
- Animal / preclinical only. Evidence is largely animal or in-vitro
- No registered human trials. Nothing registered on ClinicalTrials.gov
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
TB-500 fragment is a research peptide name used for short sequences derived from thymosin beta-4, a naturally occurring protein involved in cell movement and tissue repair. The alias Ac-SDKP refers to a specific four-amino-acid fragment (N-acetyl-seryl-aspartyl-lysyl-proline) that occurs naturally and has been studied in the lab for effects on inflammation and fibrosis. Exactly which sequence is sold under the TB-500 fragment name is often unclear.
What the evidence shows
It is not FDA-approved, and human evidence is very thin, with one registered trial reaching Phase 2 and no published papers linked in the gathered data. Most claims about healing or recovery come from animal and lab studies on thymosin beta-4 or Ac-SDKP, not from confirmed human results for this product.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.